Impact of baseline and on-treatment glycemia on everolimus-exemestane efficacy in patients with hormone receptor-positive advanced breast cancer (EVERMET)

CONCLUSIONS: The impact of on-treatment glycemia on the efficacy of EVE-EXE therapy in HR+/HER2 aBC patients depends on baseline glycemia. This study lays the foundations for investigating novel therapeutic approaches to target the glucose/insulin axis in combination with PI3K/AKT/mTORC1 inhibitors in HR+/HER2 aBC patients.PMID:33785482 | DOI:10.1158/1078-0432.CCR-20-4928

Source: Clinical Cancer Research - March 31, 2021 Category: Cancer & Oncology Authors: Claudio Vernieri Federico Nichetti Luca Lalli Luca Moscetti Carlo Alberto Giorgi Gaia Griguolo Antonio Marra Giovanni Randon Carmen G Rea Francesca Ligorio Simone Scagnoli Claudia De Angelis Chiara Molinelli Agnese Fabbri Emanuela Ferraro Dario Trapani An Source Type: research